In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19.